Assistant Professor, Medicine, University of Texas Medical School, San Antonio
Hematology
Dr. Devalingam Mahalingam, MD
|
|
Give Review
Devalingam Mahalingam practices Hematology. He received 1 awards: "CMS Meaningful Use Stage 1 Certification". Devalingam Mahalingam has written publications. He has 43 publications published with PubMed. The lastest publication is: 'Effect of Food on the Pharmacokinetics of the Investigational Aurora A Kinase Inhibitor Alisertib (MLN8237) in Patients with Advanced Solid Tumors.' Devalingam Mahalingam, MD accepts Medicare payments and is listed with Medicare.gov.
Publications
- Effect of Food on the Pharmacokinetics of the Investigational Aurora A Kinase Inhibitor Alisertib (MLN8237) in Patients with Advanced Solid Tumors.
- Phase I Study of the Investigational NEDD8-Activating Enzyme Inhibitor Pevonedistat (TAK-924/MLN4924) in Patients with Advanced Solid Tumors.
- Estrogen and estrogen receptor alpha promotes malignancy and osteoblastic tumorigenesis in prostate cancer.
- Phase I study of intraVenously administered ATI-1123, a liposomal docetaxel formulation in patients with advanced solid tumors.
- Nanomechanical biomarkers of single circulating tumor cells for detection of castration resistant prostate cancer.
- Predicting success in regulatory approval from Phase I results.
- Combined autophagy and HDAC inhibition: A phase I safety, tolerability, pharmacokinetic, and pharmacodynamic analysis of hydroxychloroquine in combination with the HDA...
- Phase II study evaluating the efficacy, safety, and pharmacodynamic correlative study of dual antiangiogenic inhibition using bevacizumab in combination with sorafenib...
- Should we move beyond VEGF inhibition in metastatic colorectal cancer? Lessons from early phase clinical trials.
- A Phase I, Multicenter, Open-Label, First-in-Human, Dose-Escalation Study of the Oral Smoothened Inhibitor Sonidegib (LDE225) in Patients with Advanced Solid Tumors.
- Clinical Outcomes and Survival of Advanced Renal Cancer Patients in Phase I Clinical Trials.
- Inhibition of Hedgehog and Androgen receptor signaling pathways produced synergistic suppression of castration-resistant prostate cancer progression.
- Single-cell analysis of circulating tumor cells identifies cumulative expression patterns of EMT-related genes in metastatic prostate cancer.
- Reovirus therapy stimulates endoplasmic reticular stress, NOXA induction, and augments bortezomib-mediated apoptosis in multiple Myeloma.
- Differential activation of JNK1 isoforms by TRAIL receptors modulate apoptosis of colon cancer cell lines.
- Targeting HSP90 for cancer therapy.
- Early growth response-1 is a regulator of DR5-induced apoptosis in colon cancer cells.
- Targeting PIM kinase enhances the activity of sunitinib in renal cell carcinoma.
- Effects of supplementation with tocotrienol-rich fraction on immune response to tetanus toxoid immunization in normal healthy volunteers.
- Optimizing outcomes in patients with chronic myeloid leukemia in chronic phase: comparative safety profiles of newer agents.
- Inhibition of NEDD8-activating enzyme: a novel approach for the treatment of acute myeloid leukemia.
- Targeting aurora kinases in cancer treatment.
- The pim kinases: new targets for drug development.
- Targeting trail towards the clinic.
- A prospective randomised study of a rotary powered device (OnControl) for bone marrow aspiration and biopsy.
- Clinical activity of mammalian target of rapamycin inhibitors in solid tumors.
- Lucanthone is a novel inhibitor of autophagy that induces cathepsin D-mediated apoptosis.
- The novel Aurora A kinase inhibitor MLN8237 is active in resistant chronic myeloid leukaemia and significantly increases the efficacy of nilotinib.
- Vorinostat enhances the activity of temsirolimus in renal cell carcinoma through suppression of survivin levels.
- Nilotinib: optimal therapy for patients with chronic myeloid leukemia and resistance or intolerance to imatinib.
- Targeting sarcomas: novel biological agents and future perspectives.
- Cdc7 kinase - a new target for drug development.
- Autophagy inhibition enhances vorinostat-induced apoptosis via ubiquitinated protein accumulation.
- Emerging drugs in the treatment of pancreatic cancer.
- Targeted therapy for advanced non-small cell lung cancers: historical perspective, current practices, and future development.
- The emerging safety profile of mTOR inhibitors, a novel class of anticancer agents.
- Serosal inflammation (pleural and pericardial effusions) related to tyrosine kinase inhibitors.
- Targeting the mTOR pathway using deforolimus in cancer therapy.
- Enhanced antitumor efficacy of a DR5-specific TRAIL variant over recombinant human TRAIL in a bioluminescent ovarian cancer xenograft model.
- Acute lymphoblastic leukemia presenting with avascular necrosis of the elbow.
- TRAIL receptor signalling and modulation: Are we on the right TRAIL?
- Challenges in developing targeted therapy for pancreatic adenocarcinoma.
Conditions Treated
- Anemia
- Central Nervous System Lymphoma
- Coagulation Disorders (incl. Hemophilia)
- Deep Vein Thrombosis (DVT)
- View All
Doctors Specialties
- Hematology
Accepted Insurances
- Aetna HMO
- Choice Plus POS II
- Amerigroup (Wellpoint)
- Blue Card PPO
- Blue Choice
- Cigna HMO
- Cigna PPO
- Great West Healthcare-Cigna PPO
- Open Access Plus
- Commercial Insurance Company
- HealthSmart
- Choice Care PPO
- Preferred PPO
- Kaiser Permanente
- Mail Handlers Benefit Plan (MHBP)
- Medicaid
- Medicare MCR
- Molina
- MultiPlan PPO
- PHCS Network PPO
- State Farm
- Tricare
- Choice Plus POS
- Navigate HMO
- Navigate POS
- Options PPO
- United Healthcare
- Universal American
Awards
- CMS Meaningful Use Stage 1 Certification
Hospital
-
South Texas Veterans Health Care System -
University Health System
Drug Facts
| NPI NUMBER | 1164650859 | |
| NPPES Provider LastName | MAHALINGAM | |
| NPPES Provider FirstName | DEVALINGAM | |
| NPPES Provider ZIPCode | 782294427 | |
| NPPES Provider State | TX | |
| Specialty Description | Internal Medicine | |
| Total Claim Count | 692.0 | |
| Distinct Opioid Count | 5.0 | |
| Opioid Claim Count | 148.0 | |
| Percent Opioid Claims | 21.39 |
Helpful Reviews
Medicare Facts
| National Provider Identifier [NPI] | 1164650859 |
| Last Name Of The Provider | MAHALINGAM |
| First Name Of The Provider | DEVALINGAM |
| View All |
Similar Doctors
|
|
Dr. Drew W. Rasco, MD
 This Doctor is OpenDoctor Recommended.
|
|
Dr. Paul J. Shaughnessy, MD
This Doctor is OpenDoctor Recommended.
|
|
Dr. Syed N. Raza, MD |
|
|
Dr. Charles H. Mims Jr., MD |
|
|
Dr. John S. Renshaw, MD |
|
|
Dr. Brian R. Haney, DO |
|
|
Dr. Penelope J. Harris, MD |
|
|
Dr. Arun R. Rao, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Benjamin J. George, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Joel D. Bessman, MD
This Doctor is OpenDoctor Recommended.
|